Saturday, July 4, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Nasdaq

Lam Research’s Whiplash Week: Record High, Insider Sales, and a $600 Million China Question

SiterGedge by SiterGedge
July 4, 2026
in Nasdaq, Semiconductors, Tech & Software
0
Lam Research Stock
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

The stock of chip-equipment maker Lam Research ended a week of extremes on a sour note. After touching an all-time high of $433.33 on June 30, the shares reversed sharply and closed Friday at $351.41 — a decline of more than 10% from the peak. The selloff was fueled by a combination of insider selling, a looming growth slowdown, and new fears over US-China trade restrictions.

CEO Timothy Archer added to the unease when he disclosed plans on July 2 to sell 30,000 shares. He was not alone: other top executives had recently unloaded sizable stakes, a move that market veterans often interpret as a red flag about near-term prospects. The timing is awkward because the company’s growth trajectory is clearly decelerating. System deliveries expanded by a blistering 82% a year ago, but analysts now expect just 3% growth in 2026, pinned on cyclical shifts in the memory-chip market.

The biggest single headwind comes from China, which accounts for roughly one-third of Lam Research’s total revenue. Tougher US export controls — reportedly aimed at Chinese chipmaker Hua Hong — are expected to cost the company about $600 million in lost sales. The regulatory tightening compounds the valuation risk. Even after the week’s plunge, Lam’s stock trades at a price-to-earnings multiple of nearly 81, well above the industry average of around 76. Independent analysts at Simply Wall St argue a fairer multiple would be closer to 61, leaving the stock vulnerable to further profit-taking from a year‑to‑date gain that still stands at roughly 90%.

Should investors sell immediately? Or is it worth buying Lam Research?

Despite the near-term gloom, a chorus of brokerages has been raising price targets. Cantor Fitzgerald now sees the stock at $500, Bank of America at $480, and Susquehanna at $475. Wells Fargo and Citi both peg fair value at $450, while Mizuho lifted its target from $330 to $380, citing robust growth in the market for AI chips. The optimism is rooted in strong underlying demand for Lam’s equipment. The company posted record revenue of $5.84 billion in its fiscal third quarter and has guided for $6.6 billion in the current period — with the possibility of reaching $7 billion at the upper end of its forecast.

The AI boom remains the key catalyst for that expansion. Lam is a critical supplier of manufacturing tools for advanced semiconductors, and the surge in AI‑related spending is driving a sharp increase in demand for specialized chip‑packaging solutions. Management expects revenue from that segment to jump more than 50% in 2026, powered by the voracious need for high‑performance memory used in data centers.

For long‑term holders, there is at least a tangible reward on the horizon. The company will pay a quarterly dividend of $0.26 per share on July 8, 2026. Whether the stock can regain its lost altitude will depend on how the market weighs the immediate China-related drag against the enduring promise of AI infrastructure spending — a tension that made Lam Research one of the most volatile names in the semiconductor space this week.

Ad

Lam Research Stock: Buy or Sell?! New Lam Research Analysis from July 4 delivers the answer:

The latest Lam Research figures speak for themselves: Urgent action needed for Lam Research investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 4.

Lam Research: Buy or sell? Read more here...

Tags: Lam Research
SiterGedge

SiterGedge

Related Posts

SpaceX Stock
IPOs

Starbase Static Fire Clears Path for Next Starship Test as SpaceX Stock Hovers at a Crossroads

July 4, 2026
Intuit Stock
Analysis

Intuit’s Valuation Discount Is Tempting — But Lawsuits and a DIY Price War Keep Buyers at Bay

July 4, 2026
Realbotix Stock
Mergers & Acquisitions

Realbotix Faces a Pivotal Gamble: Nasdaq Listing Hinges on Supply Chain and Shareholder Approval

July 4, 2026
Next Post
Realbotix Stock

Realbotix Faces a Pivotal Gamble: Nasdaq Listing Hinges on Supply Chain and Shareholder Approval

Intuit Stock

Intuit's Valuation Discount Is Tempting — But Lawsuits and a DIY Price War Keep Buyers at Bay

Mercedes-Benz Stock

Mercedes-Benz Stock Mounts Comeback as Labor Dispute Escalates Over Soured Bonus Payments

Recommended

Ford Stock

Ford’s Strategic Pivot Under Investor Scrutiny Ahead of Earnings

5 months ago
Procter & Gamble Stock

Procter & Gamble: A Defensive Haven in Turbulent Markets

10 months ago
Finances (2)

Stifel Analyst Reaffirms Buy Rating and Raises Price Target for Align Technology

2 years ago
Rocket Lab USA Stock

Strategic Expansion and Record Contracts Fuel Rocket Lab’s Momentum

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Intuit’s Valuation Discount Is Tempting — But Lawsuits and a DIY Price War Keep Buyers at Bay

Realbotix Faces a Pivotal Gamble: Nasdaq Listing Hinges on Supply Chain and Shareholder Approval

Lam Research’s Whiplash Week: Record High, Insider Sales, and a $600 Million China Question

ImmunityBio’s 369% Surge Meets 13% Short Interest — A Collision Course in Biotech

Onco-Innovations’ Share-Linked Payment Plan Threatens Dilution Even as Nanosoft Boosts ONC010 Manufacturing

TSMC Wins Approval for $44 Billion Arizona Buildout as AI Boom Powers Pricing Power

Trending

Outlook Therapeutics Stock
Analysis

Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010

by Rodolfo Hanigan
July 4, 2026
0

July is shaping up as a binary-riddled month for the small-cap biopharma. Two weeks after shareholders cast...

SpaceX Stock

Starbase Static Fire Clears Path for Next Starship Test as SpaceX Stock Hovers at a Crossroads

July 4, 2026
Mercedes-Benz Stock

Mercedes-Benz Stock Mounts Comeback as Labor Dispute Escalates Over Soured Bonus Payments

July 4, 2026
Intuit Stock

Intuit’s Valuation Discount Is Tempting — But Lawsuits and a DIY Price War Keep Buyers at Bay

July 4, 2026
Realbotix Stock

Realbotix Faces a Pivotal Gamble: Nasdaq Listing Hinges on Supply Chain and Shareholder Approval

July 4, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Outlook Therapeutics Braces for a Five-Day Gauntlet: Shareholder Vote on Survival Followed by FDA Decision on ONS-5010
  • Starbase Static Fire Clears Path for Next Starship Test as SpaceX Stock Hovers at a Crossroads
  • Mercedes-Benz Stock Mounts Comeback as Labor Dispute Escalates Over Soured Bonus Payments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com